abstract |
Provided is a formulation of androgen receptor inhibitor HC-1119 prepared from the following raw materials at the weight ratio: 1 to 100 parts of the androgen receptor inhibitor HC-1119, 100 to 1000 parts of a solvent, and 0.11 to 11 parts of an antioxidant. Also provided is a HC-1119 soft capsule and a HC-1119 formulation. The HC-1119 raw material is dissolved in Labrasol so as to significantly improve the solubility of HC-1119, and thus greatly improve the bioavailability, reduce the difference in blood drug concentration and exposure among individuals, and increase the safety of medication. Further, the HC-1119 soft capsule has good stability. |